MENU
+Compare
CLDX
Stock ticker: NASDAQ
AS OF
Jun 6, 04:58 PM (EDT)
Price
$21.35
Change
+$1.82 (+9.32%)
Capitalization
1.3B

CLDX Celldex Therapeutics Forecast, Technical & Fundamental Analysis

Celldex Therapeutics Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CLDX with price predictions
Jun 05, 2025

CLDX in upward trend: price rose above 50-day moving average on May 29, 2025

CLDX moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend. In of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for CLDX crossed bullishly above the 50-day moving average on April 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 236 cases where CLDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where CLDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on May 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDX as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CLDX turned negative on May 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.858) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). CLDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (172.414) is also within normal values, averaging (263.647).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CLDX is expected to report earnings to rise 12.07% to -79 cents per share on August 07

Celldex Therapeutics CLDX Stock Earnings Reports
Q2'25
Est.
$-0.80
Q1'25
Beat
by $0.03
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.05
The last earnings report on May 05 showed earnings per share of -70 cents, beating the estimate of -74 cents. With 304.42K shares outstanding, the current market capitalization sits at 1.30B.
A.I. Advisor
published General Information

General Information

a developer of immunotherapy technologies for the treatment of cancer and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
53 Frontage Road
Phone
+1 908 200-7500
Employees
160
Web
https://www.celldex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NGDCX28.09N/A
N/A
Neuberger Berman Large Cap Growth C
VEVRX44.81N/A
N/A
Victory Sycamore Established Value R6
HSLTX43.50N/A
N/A
Hartford Small Cap Growth R5
AFOYX15.62N/A
N/A
Ariel Focus Institutional
FNGZX18.16N/A
N/A
Franklin Intl Growth Adv

CLDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.76%
BEAM - CLDX
52%
Loosely correlated
-0.87%
DNLI - CLDX
49%
Loosely correlated
-1.35%
KYMR - CLDX
49%
Loosely correlated
+7.68%
RVMD - CLDX
49%
Loosely correlated
-0.42%
CRNX - CLDX
48%
Loosely correlated
+0.59%
More